Arnold L Potosky1, Linda C Harlan2, Karen Albritton2, Rosemary D Cress2, Debra L Friedman2, Ann S Hamilton2, Ikuko Kato2, Theresa H M Keegan2, Gretchen Keel2, Stephen M Schwartz2, Nita L Seibel2, Margarett Shnorhavorian2, Michele M West2, Xiao-Cheng Wu2. 1. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC (ALP); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (LCH); Cook Children's Medical Center and University of North Texas Health Science Center Fort Worth, TX (KA); Public Health Institute/Cancer Registry of Greater California, Sacramento, CA (RDC); Monroe Carell Jr. Children's Hospital, Vanderbilt-Ingram Cancer Center, Nashville, TN (DLF); Keck School of Medicine, University of Southern California, Los Angeles, CA (ASH); Departments of Oncology and Pathology, Wayne State University, Detroit, MI (IK); Cancer Prevention Institute of California, Fremont, CA (THMK); School of Medicine, Stanford University, Stanford, CA (THMK); Information Management Services, Inc., Silver Spring, MD (GK); Epidemiology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (SMS); Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (NLS); Department of Urology, Division of Pediatric Urology, University of Washington, Seattle Children's Hospital, Seattle, WA (MS); Department of Epidemiology, University of Iowa, Iowa City, IA (MMW); Louisiana State University, New Orleans, LA (XCW). alp49@georgetown.edu. 2. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC (ALP); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (LCH); Cook Children's Medical Center and University of North Texas Health Science Center Fort Worth, TX (KA); Public Health Institute/Cancer Registry of Greater California, Sacramento, CA (RDC); Monroe Carell Jr. Children's Hospital, Vanderbilt-Ingram Cancer Center, Nashville, TN (DLF); Keck School of Medicine, University of Southern California, Los Angeles, CA (ASH); Departments of Oncology and Pathology, Wayne State University, Detroit, MI (IK); Cancer Prevention Institute of California, Fremont, CA (THMK); School of Medicine, Stanford University, Stanford, CA (THMK); Information Management Services, Inc., Silver Spring, MD (GK); Epidemiology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (SMS); Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (NLS); Department of Urology, Division of Pediatric Urology, University of Washington, Seattle Children's Hospital, Seattle, WA (MS); Department of Epidemiology, University of Iowa, Iowa City, IA (MMW); Louisiana State University, New Orleans, LA (XCW).
Abstract
BACKGROUND: There has been little improvement in the survival of adolescent and young adult (AYA) cancer patients aged 15 to 39 years relative to other age groups, raising the question of whether such patients receive appropriate initial treatment. METHODS: We examined receipt of initial cancer treatment for a population-based sample of 504 AYAs diagnosed in 2007-2008 with acute lymphoblastic leukemia (ALL), Hodgkin's or non-Hodgkin's lymphoma, germ cell cancer, or sarcoma. Registry data, patient surveys, and detailed medical record reviews were used to evaluate the association of patient demographic, socioeconomic, and health care setting characteristics with receipt of appropriate initial treatment, which was defined by clinical specialists in AYA oncology based on adult guidelines and published literature available before 2009 and analyzed with multivariable logistic regression. All statistical tests were two-sided. RESULTS: Approximately 75% of AYA cancer patients in our sample received appropriate treatment, 68% after excluding stage I male germ cell patients who all received appropriate treatment. After this exclusion, appropriate treatment ranged from 79% of sarcoma patients to 56% of ALL patients. Cancer type (P < .01) and clinical trial participation (P = .04) were statistically significantly associated with appropriate treatment in multivariable analyses. Patients enrolled in clinical trials were more likely to receive appropriate therapy relative to those not enrolled (78% vs 67%, adjusted odds ratio = 2.6, 95% confidence interval = 1.1 to 6.4). CONCLUSIONS: Except for those with early stage male germ cell tumors, approximately 30% (or 3 in 10) AYA cancer patients did not receive appropriate therapy. Further investigation is required to understand the reasons for this potential shortfall in care delivery.
BACKGROUND: There has been little improvement in the survival of adolescent and young adult (AYA) cancerpatients aged 15 to 39 years relative to other age groups, raising the question of whether such patients receive appropriate initial treatment. METHODS: We examined receipt of initial cancer treatment for a population-based sample of 504 AYAs diagnosed in 2007-2008 with acute lymphoblastic leukemia (ALL), Hodgkin's or non-Hodgkin's lymphoma, germ cell cancer, or sarcoma. Registry data, patient surveys, and detailed medical record reviews were used to evaluate the association of patient demographic, socioeconomic, and health care setting characteristics with receipt of appropriate initial treatment, which was defined by clinical specialists in AYA oncology based on adult guidelines and published literature available before 2009 and analyzed with multivariable logistic regression. All statistical tests were two-sided. RESULTS: Approximately 75% of AYA cancerpatients in our sample received appropriate treatment, 68% after excluding stage I male germ cell patients who all received appropriate treatment. After this exclusion, appropriate treatment ranged from 79% of sarcomapatients to 56% of ALL patients. Cancer type (P < .01) and clinical trial participation (P = .04) were statistically significantly associated with appropriate treatment in multivariable analyses. Patients enrolled in clinical trials were more likely to receive appropriate therapy relative to those not enrolled (78% vs 67%, adjusted odds ratio = 2.6, 95% confidence interval = 1.1 to 6.4). CONCLUSIONS: Except for those with early stage male germ cell tumors, approximately 30% (or 3 in 10) AYA cancerpatients did not receive appropriate therapy. Further investigation is required to understand the reasons for this potential shortfall in care delivery.
Authors: Andrea Soares; Irene Biasoli; Adriana Scheliga; Ronir Raggio Luiz; Mário Alberto Costa; Marcelo Land; Sérgio Romano; José Carlos Morais; Nelson Spector Journal: Int J Cancer Date: 2007-02-15 Impact factor: 7.396
Authors: Hans Theodor Eich; Volker Diehl; Helen Görgen; Thomas Pabst; Jana Markova; Jürgen Debus; Anthony Ho; Bernd Dörken; Andreas Rank; Anca-Ligia Grosu; Thomas Wiegel; Johann Hinrich Karstens; Richard Greil; Normann Willich; Heinz Schmidberger; Hartmut Döhner; Peter Borchmann; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Andreas Engert Journal: J Clin Oncol Date: 2010-08-16 Impact factor: 44.544
Authors: Nita L Seibel; Peter G Steinherz; Harland N Sather; James B Nachman; Cynthia Delaat; Lawrence J Ettinger; David R Freyer; Leonard A Mattano; Caroline A Hastings; Charles M Rubin; Kathy Bertolone; Janet L Franklin; Nyla A Heerema; Torrey L Mitchell; Allan F Pyesmany; Mei K La; Cheryl Edens; Paul S Gaynon Journal: Blood Date: 2007-11-26 Impact factor: 22.113
Authors: Kirk R Schultz; W Paul Bowman; Alexander Aledo; William B Slayton; Harland Sather; Meenakshi Devidas; Chenguang Wang; Stella M Davies; Paul S Gaynon; Michael Trigg; Robert Rutledge; Laura Burden; Dean Jorstad; Andrew Carroll; Nyla A Heerema; Naomi Winick; Michael J Borowitz; Stephen P Hunger; William L Carroll; Bruce Camitta Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Linda C Harlan; Charles F Lynch; Theresa H M Keegan; Ann S Hamilton; Xiao-Cheng Wu; Ikuko Kato; Michele M West; Rosemary D Cress; Stephen M Schwartz; Ashley W Smith; Dennis Deapen; Sonja M Stringer; Arnold L Potosky Journal: J Cancer Surviv Date: 2011-01-28 Impact factor: 4.442
Authors: Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung Journal: Lancet Oncol Date: 2017-10-31 Impact factor: 41.316
Authors: Henry E Rice; Brian R Englum; Brian C Gulack; Obinna O Adibe; Elizabeth T Tracy; Susan G Kreissman; Jonathan C Routh Journal: Pediatr Blood Cancer Date: 2015-03-21 Impact factor: 3.167
Authors: Matthew P Banegas; John F Dickerson; Erin E Kent; Janet S de Moor; Katherine S Virgo; Gery P Guy; Donatus U Ekwueme; Zhiyuan Zheng; Stephanie Nutt; Loyce Pace; Alexandra Varga; Lisa Waiwaiole; Jennifer Schneider; K Robin Yabroff Journal: J Cancer Surviv Date: 2017-08-29 Impact factor: 4.442
Authors: Gregory F Guzauskas; Kathleen F Villa; Geertrui F Vanhove; Vicki L Fisher; David L Veenstra Journal: J Adolesc Young Adult Oncol Date: 2016-10-25 Impact factor: 2.223
Authors: Michael E Roth; Joseph M Unger; Ann M O'Mara; Mark A Lewis; Troy Budd; Rebecca H Johnson; Brad H Pollock; Charles Blanke; David R Freyer Journal: Cancer Med Date: 2020-02-03 Impact factor: 4.452
Authors: Olga Husson; Marjolijn J L Ligtenberg; Lonneke V van de Poll-Franse; Judith B Prins; Martin J van den Bent; Mies C van Eenbergen; Renske Fles; Eveliene Manten-Horst; Jourik A Gietema; Winette T A van der Graaf Journal: Cancers (Basel) Date: 2021-05-13 Impact factor: 6.639